Brege Laura 4

What Happened

• Laura Brege, a director of ACADIA PHARMACEUTICALS INC (ACAD), exercised/converted derivative rights for 8,107 shares and simultaneously had 8,107 derivative shares recorded as disposed with $0 reported proceeds. She was also granted/received two restricted stock unit (RSU) awards totaling 25,315 RSUs (16,004 + 9,311) on May 29, 2026; the grants are shown at $0.00 per share in the filing. The RSUs vested in full on May 29, 2026 (the date of the company’s annual meeting).

Key Details

• Transaction date: May 29, 2026; Form 4 filed June 1, 2026 (within typical two-business-day window).
• Derivative exercise/conversion: 8,107 shares (code M). Disposition: 8,107 shares at $0.00 reported (derivative).
• Grants/awards: 16,004 RSUs and 9,311 RSUs (codes A) — total 25,315 RSUs, reported at $0.00.
• Shares owned after transaction: not specified in the provided filing.
• Relevant footnotes from the filing:
  • F1: Each RSU equals a contingent right to one common share.
  • F2: The RSUs vested in full on May 29, 2026 (annual meeting date).
  • F3: (Related) Stock options referenced will vest quarterly over one year following grant (final tranche earlier of one year or next annual meeting).
  • F4: The RSUs will vest fully on the earlier of one year after grant or the next annual meeting; the reporting person has elected to defer receipt of the underlying shares until certain triggering events (e.g., fifth anniversary, cessation of service, or change in control).

Context

• The filing shows $0 proceeds on the disposed derivative shares, which commonly reflects a net settlement or shares withheld to cover exercise/tax obligations rather than an open-market sale. The RSUs vested but the director has elected to defer actual receipt of shares under the plan’s deferral rules (per F4). These types of award vesting and net-settlement exercises are routine compensation actions and do not by themselves indicate a buy or sell sentiment.